Leukemic Stem Cells
Leukemic Stem Cells - Related Videos
03:27
2D Co-culture of Leukemic Cells with BMSCs: A Method to Obtain Subpopulations of Leukemic Cells
0 Views •
2023
This video describes the technique for long term 2D co-culture of leukemia cells with bone marrow stromal cells to study their interaction with the bone marrow microenvironment. The 2D coculture model utilizes the acute lymphoblastic leukemia cells and the bone marrow stromal or osteoblasts that influence tumor cell phenotype. This study will support investigation of the mechanisms that underlie bone marrow supported survival of leukemic cells during chemotherapy exposure.
03:44
Leukemic Subpopulation Harvest: A Method for Spatial Separation of Leukemic Cell Subpopulations from 2D Co-culture
0 Views •
2023
This video describes a method for spatial separation of three leukemic cell subpopulations: the suspended leukemic cells freely floating in the media, phase bright leukemic cells adhered to the surface of the mesenchymal stromal cell monolayer, and the phase dim leukemic cells that have migrated beneath the mesenchymal stromal cell monolayer from 2D co-culture.
04:25
Preparation of Subcellular Fractions from Leukemic Cells: A Method to Generate Cellular and Nuclear Fractions from Leukemic Cells
0 Views •
2023
This video describes the preparation of subcellular fractions from leukemic cells which is a method to generate cellular and nuclear fractions from leukemic cells. The nuclear and cytoplasmic fractions can be used for further downstream analysis.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 7 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
03:31
Methyl Cellulose-Based CFU Assay: A Method to Determine the Effect of Anti-cancer Compounds on Colony Formation in Leukemic Cells
0 Views •
2023
This video describes the protocol for methyl cellulose-based colony formation unit or CFU assay, which helps identify and count the number of colonies formed by leukemic cells in response to the treatment with anticancer compounds.
FAQs
Quiescence can help Leukemic Stem Cells persist when treatment affects actively changing malignant cells. By remaining in a less active state, these cells may avoid immediate elimination, then resume self-renewal or produce differentiated progeny afterward. This persistence matters because surviving cells can maintain leukemia and contribute to relapse, making cellular activity an important treatment consideration.
Altered signaling and resistance to cell death give LSCs survival advantages beyond their ability to self-renew. Researchers therefore examine stemness pathways, which support maintenance of stem-like behavior, together with responses linked to cell death. Understanding how these features cooperate can reveal vulnerabilities that distinguish malignant stem cells from normal hematopoietic stem cells and guide selective treatment strategies.
Bone marrow niche interactions provide context for understanding how LSCs are maintained and how they behave during disease and treatment. Researchers examine this relationship alongside surface markers and stemness pathways because cellular persistence may reflect more than intrinsic properties alone. Including the niche can improve interpretation of drug responses and support strategies aimed at eliminating malignant stem cells.
Surface markers help researchers distinguish LSCs from normal hematopoietic stem cells, but they are studied alongside molecular and treatment-related features. Comparing marker patterns with stemness pathways and drug responses provides a broader picture of whether a cell population has malignant stem-cell properties. This combined approach supports the goal of selectively eliminating LSCs without treating normal stem cells as equivalent targets.
Studies commonly bring together several lines of analysis: researchers examine LSC surface markers, evaluate stemness pathways, investigate interactions with the bone marrow niche, and compare drug responses. These complementary areas connect cellular identity with persistence and treatment behavior. The resulting profile can support comparisons between malignant and normal stem-cell populations and inform therapeutic research.
Drug-response studies can show whether a treatment affects the malignant stem-cell population or leaves cells capable of sustaining disease. Comparing responses with those of normal hematopoietic stem cells helps researchers assess selectivity rather than measuring leukemia reduction alone. These results can identify approaches aimed at eliminating cells that survive therapy and potentially seed relapse.
Because LSCs can persist during treatment and sustain leukemia, their presence is relevant to monitoring residual disease. Researchers use knowledge of LSC markers and related stem-cell features to focus on malignant populations that may remain after therapy. This perspective complements broader measures of disease response and supports evaluation of whether treatment has addressed relapse-associated cellular populations.
LSC research connects disease biology with treatment durability by focusing on cells that may remain quiescent, resist cell death, and regenerate differentiated progeny. Findings from marker studies, pathway analysis, niche investigations, and drug-response comparisons can guide strategies that target malignant stem-cell properties. The intended outcome is deeper disease control and a lower likelihood of relapse.